Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Rises By 806.3%

Oragenics, Inc. (NYSEAMERICAN:OGEN) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 524,157 shares, a growth of 806.3% from the January 15th total of 57,838 shares. Based on an average trading volume of 1,798,797 shares, the days-to-cover ratio is currently 0.3 days. Approximately 13.7% of the shares of the company are short sold. Approximately 13.7% of the shares of the company are short sold. Based on an average trading volume of 1,798,797 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Oragenics

Several institutional investors and hedge funds have recently added to or reduced their stakes in OGEN. Clear Street LLC acquired a new position in Oragenics during the second quarter worth $270,000. Sabby Management LLC acquired a new position in shares of Oragenics during the 3rd quarter worth about $77,000. Finally, Bank of America Corp DE raised its position in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares during the last quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Stock Down 1.3%

Shares of NYSEAMERICAN OGEN traded down $0.01 during midday trading on Wednesday, reaching $0.71. 10,531 shares of the stock were exchanged, compared to its average volume of 679,697. The firm has a market cap of $3.03 million, a price-to-earnings ratio of -0.06 and a beta of 1.13. The firm has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $1.07. Oragenics has a twelve month low of $0.63 and a twelve month high of $9.60.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.